3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
4
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Prostatic Neoplasms
53
Lymphoma
44
Lymphoma, Large B-Cell, Diffuse
35
Lymphoma, Follicular
31
Precursor Cell Lymphoblastic Leukemia-Lymphoma
22
Lymphoma, Non-Hodgkin
22
Multiple Myeloma
19
Leukemia
17
Burkitt Lymphoma
13
Hodgkin Disease
12
Lymphoma, Mantle-Cell
10
Neoplasms
8
Lymphoma, Large-Cell, Immunoblastic
8
Lymphoma, B-Cell, Marginal Zone
8
Lymphoma, Large-Cell, Anaplastic
7
Neoplasms, Plasma Cell
6
Neoplasm Metastasis
6
Lymphoma, T-Cell, Peripheral
6
Recurrence
4
Leukemia, Lymphocytic, Chronic, B-Cell
4
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Pain
3
Lymphoma, B-Cell
3
Prostatic Neoplasms, Castration-Resistant
2
Prostate Cancer Metastatic
2
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
2
Myasthenia Gravis
2
Leukemia, Biphenotypic, Acute
2
Disease
2
Interventions
Rituximab
2
Epoetin Alfa
2
Early Intervention, Educational
2
Dexamethasone
2
Darbepoetin alfa
2
Bortezomib
2
ponatinib
1
pegaspargase
1
isatuximab
1
ibrutinib
1
ibritumomab tiuxetan
1
ferrous sulfate
1
ferric gluconate
1
ferric carboxymaltose
1
cirmtuzumab
1
blinatumomab
1
asparaginase erwinia chrysanthemi recombinant
1
acalabrutinib
1
Vorinostat
1
Vincristine
1
Sucrose
1
Prednisone
1
Methotrexate
1
Melphalan
1
Lenalidomide
1
Imatinib Mesylate
1
Ifosfamide
1
Etoposide
1
Doxorubicin
1
Daunorubicin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Lymphoproliferative Disorders
×
Prednisone
×
Clear all
NCT04529772
2026-03-31
ESCALADE
Acerta Pharma BV
Phase 3
Active not recruiting
611 enrolled